Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod effects on meningeal inflammation and glial activation in relapsing multiple sclerosis
2023-000018-16Phase 4Active
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ozanimod in multiple sclerosis (MS), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoint: CSF and serum CXCL13 concentration. Started Jan 2023; status: active.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2023-000018-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000018-16.